Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model

Jia,Yanyan; Yin,Yuelan; Duan,Feifei; Fu,Hong; Hu,Maozhi; Gao,Yunfei; Pan,Zhiming; Jiao,Xinan

doi:10.3892/ijmm.2012.1136

Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model

Authors:
- Yanyan Jia
- Yuelan Yin
- Feifei Duan
- Hong Fu
- Maozhi Hu
- Yunfei Gao
- Zhiming Pan
- Xinan Jiao
View Affiliations

Affiliations: Jiangsu Key Laboratory of Zoonosis, Yangzhou University, Yangzhou, Jiangsu 225009, P.R. China
Published online on: September 20, 2012 https://doi.org/10.3892/ijmm.2012.1136
Pages: 1335-1342

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Listeria monocytogenes (L. monocytogenes) has been developed as a cancer vaccine vector due to its ability to elicit strong innate and adaptive immune responses. For clinical application, it is necessary to exploit a Listeria platform strain that is safe and that also retains its immunogenicity to develop vaccine candidates against cancer. In this study, a highly attenuated strain with a deletion of actA/plcB was employed as a vector to deliver the human papillomavirus type 16 (HPV16) E7 antigen, which was stably inserted into the chromosome of L. monocytogenes. The prophylactic and therapeutic efficacy of the recombinant L. monocytogenes strain expressing E7 (LM1-2-E7) were evaluated in C57BL/6 mice. In prophylactic tumor challenge assays, immunization with the recombinant strain LM1-2-E7 was able to protect against tumor formation in 87.5% of the mice, even after a second challenge, suggesting that this prophylactic immunization can provide long-lasting immunity. In the therapeutic setting, immunization with LM1-2-E7 led to tumor regression in 50% of the mice and suppressed tumor growth in the remaining mice. The results showed that the recombinant strain was cleared by the immune system within 5 days after immunization and induced a Th1 immune response against E7 peptide and E7-specific cytotoxic T-lymphocyte (CTL) killing activity without severe inflammatory responses in the spleen and liver. Markedly, recombinant Listeria strain resulted in preferential accumulation within tumor tissues and induced higher numbers of CD8+ T cells that infiltrated into the tumor, which were associated with retardation of tumor growth. Collectively, these data indicate that LM1-2-E7 is a possible vaccine candidate against cervical cancer.

View Figures

View References

1.	J CohenPublic health. High hopes and dilemmas for a cervical cancer vaccineScience308618621200510.1126/science.308.5722.61815860602
2.	A JemalF BrayMM CenterJ FerlayE WardD FormanGlobal cancer statisticsCA Cancer J Clin616990201110.3322/caac.20107
3.	G GattaMB LasotaA VerdecchiaSurvival of European women with gynaecological tumours, during the period 1978–1989. EUROCARE Working GroupEur J Cancer3422182225199810070290
4.	A SchäferW FriedmannM MielkeB SchwartländerMA KochThe increased frequency of cervical dysplasia-neoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppressionAm J Obstet Gynecol16459359919911992708
5.	RM HauptC SattlerHPV vaccine continues to be safe and effective, and its benefits continue to outweigh its risksExpert Rev Vaccines9697701201010.1586/erv.10.5620624041
6.	TC WuTherapeutic human papillomavirus DNA vaccination strategies to control cervical cancerEur J Immunol37310314200710.1002/eji.20063697817273998
7.	H zur HausenPapillomaviruses and cancer: from basic studies to clinical applicationNat Rev Cancer2342350200212044010
8.	CF HungTC WuA MonieR RodenAntigen-specific immunotherapy of cervical and ovarian cancerImmunol Rev2224369200810.1111/j.1600-065X.2008.00622.x18363994
9.	V ShahabiMM SeaveyPC MaciagS RiveraA WallechaDevelopment of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in humanCancer Gene Ther185362201120725099
10.	M TangneyCG GahanListeria monocytogenes as a vector for anti-cancer therapiesCurr Gene Ther104655201010.2174/156652310790945539
11.	KW BruhnN CraftJF MillerListeria as a vaccine vectorMicrobes Infect912261235200710.1016/j.micinf.2007.05.010
12.	LA ZenewiczH ShenInnate and adaptive immune responses to Listeria monocytogenes: a short overviewMicrobes Infect912081215200710.1016/j.micinf.2007.05.00817719259
13.	A DarjiW MohamedE DomannT ChakrabortyInduction of immune responses by attenuated isogenic mutant strains of Listeria monocytogenesVaccine21Suppl 2102109200310.1016/S0264-410X(03)00208-112763691
14.	LM WoodZK PanP GuirnaldaP TsaiM SeaveyY PatersonTargeting tumor vasculature with novel Listeria-based vaccines directed against CD105Cancer Immunol Immunother60931942201110.1007/s00262-011-1002-x21431419
15.	A WallechaPC MaciagS RiveraY PatersonV ShahabiConstruction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapyClin Vaccine Immunol16961032009
16.	MM SeaveyZK PanPC MaciagA novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumorsClin Cancer Res15924932200919188163
17.	PC MaciagS RadulovicJ RothmanThe first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervixVaccine2739753983200919389451
18.	DA SewellZK PanY PatersonListeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumorsVaccine2653155320200810.1016/j.vaccine.2008.07.036
19.	GR GunnA ZubairC PetersZK PanTC WuY PatersonTwo Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16J Immunol16764716479200111714814
20.	A WallechaC FrenchR PetitR SinghA AminJ RothmanLm-LLO-based immunotherapies and HPV-associated diseaseJ Oncol2012542851201210.1155/2012/54285122481930
21.	T VerchZK PanY PatersonListeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccinesInfect Immun7264186425200410.1128/IAI.72.11.6418-6425.2004
22.	P CossartA Toledo-AranaListeria monocytogenes, a unique model in infection biology: an overviewMicrobes Infect1010411050200810.1016/j.micinf.2008.07.043
23.	EG PamerImmune responses to Listeria monocytogenesNat Rev Immunol4812823200410.1038/nri1461
24.	D SchlüterE DomannC BuckPhosphatidylcholine-specific phospholipase C from Listeria monocytogenes is an important virulence factor in murine cerebral listeriosisInfect Immun66593059381998
25.	H AngelakopoulosK LoockDM SisulER JensenJF MillerEL HohmannSafety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculationInfect Immun7035923601200212065500
26.	DG BrockstedtTW DubenskyPromises and challenges for the development of Listeria monocytogenes-based immunotherapiesExpert Rev Vaccines710691084200810.1586/14760584.7.7.106918767955
27.	IR MonkCG GahanC HillTools for functional post-genomic analysis of Listeria monocytogenesAppl Environ Microbiol7439213934200810.1128/AEM.00314-0818441118
28.	Y YinD TianH JiaoPathogenicity and immunogenicity of a mutant strain of Listeria monocytogenes in the chicken infection modelClin Vaccine Immunol18500505201110.1128/CVI.00445-1021228136
29.	X JiaoR Lo-ManN WinterE DériaudB GicquelC LeclercThe shift of Th1 to Th2 immunodominance associated with the chronicity of Mycobacterium bovis bacille Calmette- Guérin infection does not affect the memory responseJ Immunol17013921398200310.4049/jimmunol.170.3.139212538699
30.	P BerraondoC NouzéX PrévilleD LadantC LeclercEradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune systemCancer Res6788478855200710.1158/0008-5472.CAN-07-032117875726
31.	S NaitoAC von EschenbachR GiavazziIJ FidlerGrowth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude miceCancer Res464109411519863731078
32.	K LinK DoolanCF HungTC WuPerspectives for preventive and therapeutic HPV vaccinesJ Formos Med Assoc109424201010.1016/S0929-6646(10)60017-420123582
33.	YL YinCJ ZhangDB TianZM PanXA JiaoKinetics of mutant Listeria monocytogenes strain yzuLM1-2 in murine infection modelVet Sci in China378508532007
34.	A de JongJM van der HulstGG KenterRapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancerInt J Cancer114274282200515540211
35.	MD VeselyMH KershawRD SchreiberMJ SmythNatural innate and adaptive immunity to cancerAnnu Rev Immunol29235271201110.1146/annurev-immunol-031210-10132421219185
36.	YA YuS ShabahangTM TimiryasovaVisualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteinsNat Biotechnol22313320200410.1038/nbt93714990953
37.	C GravekampY PatersonHarnessing Listeria monocytogenes to target tumorsCancer Biol Ther92572652010
38.	Q ZengS PengA MonieControl of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agentsHum Gene Ther22809819201010.1089/hum.2010.07121128743
39.	RK SharmaRH SchabowskyAK Srivastava4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccinesCancer Res7039453954201010.1158/0008-5472.CAN-09-4480
40.	S Ostrand-RosenbergAnimal models of tumor immunity, immunotherapy and cancer vaccinesCurr Opin Immunol16143150200410.1016/j.coi.2004.01.00315023405